| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
118,790,000 |
| Market
Cap: |
42.71(M) |
| Last
Volume: |
19,275,386 |
Avg
Vol: |
9,059,070 |
| 52
Week Range: |
$0.3595 - $0.3595 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M™ adjuvant.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
6,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kelly James Patrick |
EVP, CFO and Treasurer |
• – – |
2024-03-10 |
4 |
D |
$5.45 |
$12,132 |
D/D |
(2,226) |
13,285 |
|
- |
|
| Kelly James Patrick |
EVP, CFO and Treasurer |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,608 |
15,511 |
|
- |
|
| Trizzino John |
President and COO |
• – – |
2024-03-10 |
4 |
D |
$5.45 |
$12,132 |
D/D |
(2,226) |
27,972 |
|
- |
|
| Trizzino John |
President and COO |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,608 |
30,198 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2024-03-10 |
4 |
D |
$5.45 |
$14,154 |
D/D |
(2,597) |
66,613 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2024-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,376 |
69,210 |
|
- |
|
| Kelly James Patrick |
EVP, CFO and Treasurer |
• – – |
2024-03-07 |
4 |
D |
$5.61 |
$33,127 |
D/D |
(5,905) |
10,903 |
|
- |
|
| Kelly James Patrick |
EVP, CFO and Treasurer |
• – – |
2024-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,224 |
16,808 |
|
- |
|
| Trizzino John |
EVP, CCO and CBO |
• – – |
2024-03-07 |
4 |
D |
$5.61 |
$78,288 |
D/D |
(13,955) |
25,590 |
|
- |
|
| Trizzino John |
EVP, CCO and CBO |
• – – |
2024-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
28,890 |
39,545 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2024-03-07 |
4 |
D |
$5.61 |
$52,689 |
D/D |
(9,392) |
63,834 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2024-03-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,444 |
73,226 |
|
- |
|
| Ohara Elaine |
EVP, Chief Strategy Officer |
• – – |
2024-03-01 |
4 |
D |
$5.39 |
$28,971 |
D/D |
(5,375) |
14,225 |
|
- |
|
| Ohara Elaine |
EVP, Chief Strategy Officer |
• – – |
2024-03-01 |
4 |
OE |
$5.39 |
$105,644 |
D/D |
19,600 |
19,600 |
|
- |
|
| Jacobs John C |
President and CEO |
• • – |
2024-01-23 |
4 |
D |
$4.26 |
$170,796 |
D/D |
(40,093) |
43,104 |
|
- |
|
| Jacobs John C |
President and CEO |
• • – |
2024-01-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
83,197 |
83,197 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2023-12-14 |
4 |
D |
$5.69 |
$3,983 |
D/D |
(700) |
13,233 |
|
- |
|
| Herrmann John A Iii |
EVP, Chief Legal Officer |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,100 |
13,933 |
|
- |
|
| Trizzino John |
EVP, CCO and CBO |
• – – |
2023-12-14 |
4 |
D |
$5.69 |
$4,398 |
D/D |
(773) |
10,655 |
|
- |
|
| Trizzino John |
EVP, CCO and CBO |
• – – |
2023-12-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,600 |
11,428 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2023-12-14 |
4 |
D |
$5.69 |
$7,784 |
D/D |
(1,368) |
53,782 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2023-12-14 |
4 |
OE |
$5.69 |
$16,120 |
D/D |
2,833 |
55,150 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2023-11-05 |
4 |
D |
$7.06 |
$4,780 |
D/D |
(677) |
52,317 |
|
- |
|
| Dubovsky Filip |
President, R&D |
• – – |
2023-11-05 |
4 |
OE |
$7.06 |
$9,884 |
D/D |
1,400 |
52,994 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2023-10-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,800 |
3,800 |
|
- |
|
602 Records found
|
|
Page 1 of 25 |
|
|
